All GLP-1 medications from licensed 503A compounding pharmacies Browse Products

Wegovy And Gallbladder?

Wegovy may increase the risk of gallstones and gallbladder inflammation due to rapid weight loss. Learn what the STEP trials found, warning signs, and...

By FormBlends Editorial Research||
In This Article

This article is part of our GLP-1 Weight Loss collection. See also: Provider Comparisons | Peptide Guides

Key Takeaway

See your GLP-1 options in about 2 minutes. Free and private. See my options →

Wegovy may increase the risk of gallstones and gallbladder inflammation due to rapid weight loss. Learn what the STEP trials found, warning signs, and protective strategies.

Wegovy (semaglutide 2.4 mg) may increase the risk of gallbladder problems, including gallstones and gallbladder inflammation. In the STEP 1[1] clinical trial, gallbladder-related events occurred in about 2.6 percent of patients taking Wegovy versus 1.2 percent on placebo. This risk is primarily linked to the substantial weight loss the medication produces rather than a direct toxic effect.

Detailed Answer

Wegovy is the weight-management formulation of semaglutide, dosed at 2.4 mg weekly. It produces average weight loss of 15 to 17 percent of body weight over 68 weeks in clinical trials, making it one of the most effective non-surgical weight loss treatments available. But weight loss of this magnitude carries a well-established risk of gallbladder complications, and the STEP trial data reflects this.

Why Wegovy Increases Gallbladder Risk

The connection between weight loss and gallstones has been understood for decades. When you lose weight, particularly at a rapid pace, your liver increases cholesterol excretion into bile. Simultaneously, eating less food (and especially less fat) means your gallbladder contracts less frequently. The result is cholesterol-saturated bile pooling in a gallbladder that isn't emptying as it should. Over time, this bile crystallizes into gallstones.

Wegovy amplifies this risk through two mechanisms. First, the significant weight loss itself changes bile composition. Second, GLP-1 receptor activation may directly reduce gallbladder motility, since GLP-1 receptors are present in gallbladder tissue. Both effects contribute to the conditions that promote stone formation.

STEP Trial Gallbladder Data

Across the STEP trial program, gallbladder-related events were consistently more common in semaglutide-treated patients than in placebo groups. In STEP 1, the rate was 2.6 percent vs. 1.2 percent. Most events were cholelithiasis (gallstones) or cholecystitis (gallbladder inflammation). A small number of patients required cholecystectomy (surgical gallbladder removal). The risk was higher among patients who lost the most weight, which supports the weight-loss-driven mechanism.

Risk Factors for Gallbladder Problems on Wegovy

Not everyone on Wegovy will develop gallbladder issues. Your risk is influenced by:

  • Rate of weight loss. Losing more than 1.5 kg (3.3 pounds) per week consistently increases risk substantially.
  • Sex. Women develop gallstones at roughly twice the rate of men, due to the effects of estrogen on bile composition.
  • Age. Risk increases after age 40.
  • Prior gallstone history. If you have had gallstones before, you're at higher risk of recurrence during rapid weight loss.
  • Diet composition. Very low-fat diets reduce gallbladder contraction frequency, promoting stasis. best diet while taking Wegovy

Protective Strategies

The most actionable step is to include moderate amounts of healthy fat at every meal. Olive oil, avocados, nuts, seeds, and fatty fish all stimulate gallbladder emptying and help prevent bile stasis. You don't need a high-fat diet, just enough fat to keep the gallbladder active. Staying well hydrated also helps maintain healthy bile consistency. If you have known risk factors, your physician may suggest periodic abdominal ultrasounds to monitor for early stone formation.

What You Need to Know

  • Gallbladder problems are an uncommon but documented risk with Wegovy, occurring in about 2 to 3 percent of patients.
  • The risk scales with the amount and speed of weight loss, not the medication dose alone.
  • Eating moderate amounts of healthy fat at each meal is a simple, effective protective measure.
  • Know the difference between typical Wegovy nausea (mild, diffuse, temporary) and gallbladder symptoms (sudden, severe, localized to upper right abdomen).
  • Patients who have already had their gallbladder removed can use Wegovy without this particular risk.
  • Inform your physician about any history of gallbladder disease before starting Wegovy.

How can I protect my gallbladder while taking Wegovy?

Include healthy fats (olive oil, avocado, nuts, fatty fish) at each meal to keep your gallbladder contracting regularly. Avoid crash-level caloric restriction beyond what Wegovy naturally produces. Stay hydrated. If you have gallbladder risk factors, discuss monitoring options like periodic ultrasounds with your physician. Maintaining steady, moderate-paced weight loss rather than dramatic rapid loss also reduces your risk. For a complete cost breakdown, see our affordable GLP-1 options.

Check your GLP-1 eligibility

Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.

Try the BMI Calculator →
GLP-1 Weight Loss Results by Medication Mean Body Weight Loss (%) 0 6 12 18 24 22 15 8 24 Tirzepatide Semaglutide Liraglutide Retatrutide Based on published STEP and SURMOUNT trial data
GLP-1 Weight Loss Results by Medication. Based on published STEP and SURMOUNT trial data.
View data table
Bar chart showing glp-1 weight loss results by medication: Tirzepatide (22), Semaglutide (15), Liraglutide (8), Retatrutide (24)
CategoryMean Body Weight Loss (%)Detail
Tirzepatide22~22% body weight at 72 wks
Semaglutide15~15% body weight at 68 wks
Liraglutide8~8% body weight at 56 wks
Retatrutide24~24% in Phase 2 trial
Illustration for Wegovy And Gallbladder?

Should I get my gallbladder checked before starting Wegovy?

If you have a personal history of gallstones, gallbladder attacks, or biliary disease, inform your prescribing physician. They may recommend a baseline abdominal ultrasound and more frequent monitoring during treatment. A history of gallbladder problems doesn't automatically disqualify you from Wegovy therapy, but it does mean you and your provider should be extra vigilant about warning signs.

What happens if I develop gallstones on Wegovy?

If gallstones are detected but not causing symptoms, your physician may recommend monitoring while continuing treatment. If you develop symptomatic gallstones (pain, inflammation), treatment typically involves pain management and may ultimately require cholecystectomy (gallbladder removal). The decision to continue or pause Wegovy will depend on the severity of your gallbladder condition and your overall treatment goals. Your physician will guide this decision.

Can Wegovy cause gallbladder attacks?

Wegovy itself doesn't directly trigger gallbladder attacks. But if gallstones have formed (whether from Wegovy-related weight loss or pre-existing), eating a fatty meal can cause a gallstone to temporarily block a bile duct, resulting in a gallbladder attack (biliary colic). Symptoms include intense pain in the upper right abdomen, typically lasting 30 minutes to several hours. If you experience this, seek medical attention promptly.

Medical References

  1. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989-1002. [PubMed | ClinicalTrials.gov | DOI]

Take the Next Step

Physician supervision helps catch gallbladder and other potential issues early. FormBlends.com provides thorough telehealth consultations for Wegovy therapy, including medical history review, ongoing monitoring, and personalized nutritional guidance to support your safety throughout treatment.

See your options in about 2 minutes

Take the free quiz and see what fits you. Quick, private, and no commitment to continue.

See my options →
Wegovy And Gallbladder? custom 2026 header image for GLP-1 Weight Loss
Custom header image for Wegovy And Gallbladder?, GLP-1 Weight Loss, and better treatment decision-making.

Research Snapshot

Medication guide
Page type
Medication guide
Page metadata
Page updated
2026-04-01
Page metadata
FormBlends official source
Official source
Retatrutide official website
Official source
Semaglutide official website
Official source
Tirzepatide official website
Official source
Wegovy official website
Official source
Before you act
Check the current prescribing information, regulatory status, and trial source before treating an investigational or newly approved medication as interchangeable with an established therapy.
Check before ordering

Regulatory status, labels, trial records, and sponsor updates can change quickly for obesity-drug pipeline pages. This snapshot is designed to make verification easier, not to replace checking the official source before making a medical or purchase decision. Page updated: 2026-04-01.

Continue with decision-grade research

Compare the options behind this question

These pages separate verified facts, commercial terms, and unresolved claims so you can check the evidence before choosing a provider.

GLP-1 decision path

Use this page to decide if a provider review is the right next step

Related treatment context

Wegovy And Gallbladder? research is most useful when it helps you compare eligibility, expected results, side effects, cost, and the supervision needed before treatment.

Evidence check

The strongest GLP-1 pages connect the practical answer to clinical trials, FDA labeling where applicable, and real access constraints.

Safety check

A licensed clinician still needs to review health history, contraindications, current medications, side effects, and dose escalation.

Next step

When the page matches your goal, continue into the FormBlends get-started flow so the intake can route you toward the right prescription review path.

FormBlends Editorial Context

  • Confirm whether the page is discussing an FDA-approved use, a compounded option, or research-only context.
  • Ask a licensed clinician how the evidence applies to your health history, medications, labs, and side-effect risk.
  • Check the latest label, trial update, pharmacy policy, or state rule when the article touches medication access.

Original tools and data

Use FormBlends tools and data

Compare provider prices, explore local access and check calculations using FormBlends tools and data.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication or treatment. FormBlends articles are source-checked against medical and regulatory references, but they are not a substitute for a personal medical consultation.

Written by FormBlends Editorial Research

Prepared by FormBlends Editorial Research.

Ready to get started?

Provider-reviewed GLP-1 and peptide therapy, delivered to your door.

Start Your Consultation

Ready to Start Your Weight Loss Journey?

Get a free medical consultation with a licensed provider. Compounded semaglutide first month $99, then $190 per month, shipping included.

Next Best Reads

FormBlends for iPhone

Shot days, doses and progress in one place

The free FormBlends iPhone app tracks GLP-1 doses, shot-day reminders, weight trends, meals and private progress photos.

Free Tools

Calculators to support your weight loss journey.